These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26381330)

  • 1. Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
    Lovering F; Aevazelis C; Chang J; Dehnhardt C; Fitz L; Han S; Janz K; Lee J; Kaila N; McDonald J; Moore W; Moretto A; Papaioannou N; Richard D; Ryan MS; Wan ZK; Thorarensen A
    ChemMedChem; 2016 Jan; 11(2):217-33. PubMed ID: 26381330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
    Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
    Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
    Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.
    Wang L; Stanley M; Boggs JW; Crawford TD; Bravo BJ; Giannetti AM; Harris SF; Magnuson SR; Nonomiya J; Schmidt S; Wu P; Ye W; Gould SE; Murray LJ; Ndubaku CO; Chen H
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4546-4552. PubMed ID: 25139565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
    Riccaboni M; Bianchi I; Petrillo P
    Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1.
    Cheung M; Kuntz KW; Pobanz M; Salovich JM; Wilson BJ; Andrews CW; Shewchuk LM; Epperly AH; Hassler DF; Leesnitzer MA; Smith JL; Smith GK; Lansing TJ; Mook RA
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6214-7. PubMed ID: 18929484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
    Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
    J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and profiling of a selective and efficacious Syk inhibitor.
    Thoma G; Smith AB; van Eis MJ; Vangrevelinghe E; Blanz J; Aichholz R; Littlewood-Evans A; Lee CC; Liu H; Zerwes HG
    J Med Chem; 2015 Feb; 58(4):1950-63. PubMed ID: 25633741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
    Thorarensen A; Kaila N
    Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent aminopyridines as Syk kinase inhibitors.
    Castillo M; Forns P; Erra M; Mir M; López M; Maldonado M; Orellana A; Carreño C; Ramis I; Miralpeix M; Vidal B
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5419-23. PubMed ID: 22877633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
    Norman P
    Expert Opin Ther Pat; 2012 Mar; 22(3):335-9. PubMed ID: 22356552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
    Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.